This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: Q87.2 | Special Copayment Reduction: V243 | Recertification cycle: 5 years |
| B. Synonyms | Rubinstein-Taybi syndrome, VATER syndrome, Klippel-Trénaunay-Weber syndrome, Holt-Oram syndrome, nail-patella syndrome |
| C. Adult onset | Varies by syndrome — Rubinstein-Taybi, Holt-Oram, and nail-patella syndromes persist into adulthood after diagnosis in childhood; in Klippel-Trénaunay-Weber syndrome, some patients first present in adulthood with vascular complications |
| Section | Summary |
|---|---|
| 1. History | A group of complex congenital limb malformation syndromes—Rubinstein-Taybi (1963), Holt-Oram (1960), Klippel-Trénaunay (1900), VATER (1972), and others—whose clinical descriptions and molecular bases were established from the mid-20th century onward. |
| 2. Causes | Causative genes differ by syndrome. CREBBP/EP300 (Rubinstein-Taybi), TBX5 (Holt-Oram), LMX1B (nail-patella), VEGFR3/PIK3CA (Klippel-Trénaunay), multifactorial (VATER). |
| 3. Genetics | Mostly autosomal dominant inheritance (Rubinstein-Taybi, Holt-Oram, nail-patella); Klippel-Trénaunay is mainly due to somatic mosaic mutations; VATER occurs sporadically. |
| 4. General epidemiology | Rubinstein-Taybi 1/125,000, Holt-Oram 1/100,000, nail-patella 1/50,000, Klippel-Trénaunay 1/20,000–100,000, VATER 1.6/10,000 births. |
| 5. Pathophysiology | Abnormalities in pathways of transcription factors regulating limb development, chromatin remodeling, angiogenesis, and renal and cardiac development overlap, causing combined malformations of the limbs and associated organs. |
| 6. Symptoms | Broad thumbs and great toes, intellectual disability, and facial anomalies (Rubinstein-Taybi); upper limb and cardiac malformations (Holt-Oram); vascular malformations and limb hypertrophy (Klippel-Trénaunay); vertebral, anal, cardiac, esophageal, renal, and limb anomalies (VATER); nail and patellar dysplasia (nail-patella). |
| 7. Signs | Characteristic physical findings of each syndrome: clinical examination findings such as broad thumbs, distinctive facial features, radial limb dysplasia, vascular malformations, nail dysplasia, and absent or hypoplastic patellae. |
| 8. Screening | Detection of limb abnormalities on prenatal ultrasound is the main screening opportunity. After recognition of the clinical phenotype in the neonatal period, confirmed by gene panel testing. |
| 9. Diagnosis | After clinical diagnostic criteria are met, confirmed by molecular genetic testing of causative genes (NGS panel, WES). Evaluation of associated abnormalities by echocardiography, renal ultrasound, ophthalmological examination, etc. |
| 10. Treatment | No curative treatment; centered on surgical correction of limb malformations, treatment of cardiac and renal complications, early educational intervention for intellectual disability and developmental delay, and sclerotherapy or surgical treatment of vascular malformations. |
| 11. Prognosis | Prognosis determined by cardiac malformations, renal function, and degree of intellectual disability. Holt-Oram allows normal life expectancy with appropriate cardiac treatment; VATER varies with the extent of congenital malformations. |
| 12. Prevention | Genetic counseling, prenatal genetic testing (CVS, amniocentesis), preimplantation genetic testing (PGT-M), carrier identification in families with a family history. |
| 13. References | 10 recent references (with PMID/DOI) |
'Congenital malformation syndromes predominantly involving limbs,' classified under code Q87.2, is not a single disease but a heterogeneous group of syndromes sharing limb malformations as a main feature. The main syndromes in this category each have their own independent clinical and molecular genetic history.
Rubinstein-Taybi syndrome (RSTS) was first defined in 1963 when the American pediatricians Jack H. Rubinstein and Hooshang Taybi described 7 pediatric cases sharing broad, flat thumbs and great toes, a distinctive facial appearance, and intellectual disability. Subsequently, in 1991 deletions of the short arm of chromosome 16 were reported in some patients, and in 1995 Petrij and colleagues first demonstrated that variants in the CREBBP (CREB binding protein) gene are the cause. In 2001, EP300 gene variants were shown to cause a clinically similar syndrome.
Holt-Oram syndrome (HOS) was named after the British physicians Mary Holt and Samuel Oram, who in 1960 reported a family with coexisting atrial septal defect and upper limb malformations. Subsequently, in 1994 the TBX5 gene was identified on the long arm of chromosome 12 (12q24.1), and in 1997 Li and colleagues identified pathogenic TBX5 variants.
Klippel-Trénaunay-Weber syndrome (KTWS) was first described in 1900 by Klippel and Trénaunay of France as a three-symptom complex of port-wine stain, venous malformations, and limb hypertrophy, and Weber additionally described arteriovenous fistulas. At the molecular level, the association with somatic PIK3CA mutations was elucidated from the 2010s onward.
Along with Holt-Oram syndrome, VATER syndrome (VATER/VACTERL association) was defined in 1972 by Quan and Smith, who compiled cases in which vertebral, anorectal, tracheo-esophageal, renal, and limb anomalies coexisted nonrandomly. VACTERL is the expanded name adding cardiac anomalies. An exact single-gene cause has not yet been identified, and it is regarded as a heterogeneous syndrome.
Nail-patella syndrome (NPS) was first described in 1897 by Little in a family with nail and patellar dysplasia, and in 1998 Dreyer and colleagues identified the LMX1B gene as the cause. LMX1B is a key transcription factor for the development of dorsal limb structures and the glomerular basement membrane. For all of these syndromes, the current diagnostic framework was established through clinical descriptions in the mid-to-late 20th century and advances in molecular genetics since the 1990s.
The syndromes in this category arise from different genes and genetic mechanisms, but abnormalities in embryonic limb development pathways are the common core pathogenesis.
Rubinstein-Taybi syndrome is caused by pathogenic variants in the CREBBP gene (16p13.3) or the EP300 gene (22q13.2), which encode histone acetyltransferases. CREBBP variants account for about 55% and EP300 variants about 8–10%, and the cause is not identified in the remainder. Both genes encode histone acetyltransferases (HAT) involved in transcriptional regulation and chromatin remodeling, and loss of this function has broad effects on limb development, facial formation, and neurodevelopment.
The cause of Holt-Oram syndrome is variants in the transcription factor TBX5 (12q24.1) gene. TBX5 belongs to the T-box transcription factor family and plays a key regulatory role in both upper limb development and cardiac development. Because it simultaneously regulates specific pathways of finger, radial, and cardiac development, it explains the characteristic clinical picture in which upper limb and cardiac malformations appear together.
The cause of nail-patella syndrome is variants in the LMX1B gene (9q33.3), which encodes a LIM domain transcription factor. LMX1B is involved in dorsal limb structures (nails, patella, iliac crest) and in the arrangement of type IV collagen in the glomerular basement membrane. The accompanying renal lesions (causing nephrotic syndrome) reflect the role of LMX1B in the glomerular basement membrane.
Klippel-Trénaunay-Weber syndrome is associated with somatic mosaic mutations in pathways regulating vascular development, particularly somatic activating variants of PIK3CA (PI3K/AKT/mTOR signaling pathway). Variants in other angiogenesis-related genes such as GJC2 and TEK (TIE2) have also been reported in some cases. Because somatic mosaic variants rather than germline variants are the main mechanism, most cases occur sporadically without a family history.
The cause of VATER/VACTERL association has not yet been fully elucidated. Polygenic or environment-gene interaction models have been proposed, and several genes such as ZIC3, FOXF1, and TRAP1 have been reported in some patients. There is evidence that maternal diabetes and exposure to certain drugs (valproic acid, estrogen) increase the risk. Most cases occur sporadically, and it is understood as an association caused by multiple abnormalities of developmental pathways rather than a single-gene cause.
The inheritance patterns of the syndromes in this category are diverse.
Rubinstein-Taybi syndrome is inherited in an autosomal dominant manner, and most cases (about 90% or more) are caused by de novo pathogenic variants. Familial transmission is rare, but it can be passed to a patient's children with a 50% probability. The CREBBP gene is located at 16p13.3 and consists of 31 exons. Missense, nonsense, splicing, small insertion/deletion, and large deletion (detected by microarray) variants have all been reported. It is divided into Rubinstein-Taybi locus 1 (CREBBP) and locus 2 (EP300).
Holt-Oram syndrome is also autosomal dominant; about 70% are inherited by children of families carrying a TBX5 variant, and about 30% are de novo variants. TBX5 is located at 12q24.1, and missense variants are the most common. Regarding genotype-phenotype correlation, there are reports that TBX5 T-box domain variants tend to have more severe cardiac malformations and N-terminal variants more prominent upper limb malformations, but there is much overlap. Because variability in expressivity is large, the symptom spectrum differs greatly even within families with the same variant.
Nail-patella syndrome is autosomal dominant, inherited from families with an LMX1B variant in about 88%. About 12% are de novo variants. LMX1B is located at 9q33.3 and consists of 8 exons. Penetrance is very high, so clinical symptoms appear in almost all variant carriers, but expressivity varies. Renal involvement (glomerular nephropathy) occurs in about 30–50% and can progress to renal failure.
Klippel-Trénaunay-Weber syndrome is mainly caused by somatic mosaic variants, so most cases occur sporadically without a family history. Somatic activating PIK3CA variants (gain-of-function) are found mainly confined to vascular endothelial cells and supporting cells. Germline variants are very rare.
VATER/VACTERL mostly occurs sporadically and has no established single inheritance pattern. The recurrence risk is low, 1–3%, when there is no family history. Autosomal dominant or X-linked inheritance patterns have been reported in some cases, but they are few.
Epidemiological data for the main syndromes in this category are as follows.
The birth prevalence of Rubinstein-Taybi syndrome is reported at about 1/100,000–1/125,000 births. There is no sex difference, and it occurs in all ethnic groups. Several thousand or more patients are registered worldwide, and the most research has been conducted in Europe, the United States, and Japan.
The birth prevalence of Holt-Oram syndrome is estimated at about 1/100,000. Accurate prevalence is difficult to determine because the diagnosis may be missed in mild phenotypes. Careful evaluation is needed in patients with both upper limb and cardiac malformations.
Nail-patella syndrome has a prevalence of about 1/50,000 births, relatively frequent among rare diseases. Linkage with nephrology is important in patients with renal involvement.
The birth prevalence of Klippel-Trénaunay-Weber syndrome is estimated at about 1/20,000–1/100,000. It occurs without sex difference, and the extent of vascular malformations and the degree of limb hypertrophy vary greatly among individuals. Combined care by dermatology, vascular surgery, and orthopedics is needed.
VATER/VACTERL is relatively common at about 1.6/10,000 births. Among these, cases meeting the typical VACTERL combination are fewer. There is no sex difference, and it occurs sporadically worldwide. In Korea, registration and management under Special Copayment Reduction V243 are possible. Maternal diabetes during pregnancy is known as a risk factor, and the incidence of VACTERL is higher in diabetic pregnant women than in the general population.
The congenital malformation syndromes in this category arise from abnormalities in pathways of limb development, cardiac and renal formation, and angiogenesis, respectively, and disruption of these pathways during embryonic development causes combined malformations.
In Rubinstein-Taybi syndrome, CREBBP/EP300 mediate histone H3K27 acetylation and are involved in the overall regulation of gene expression. These proteins activate downstream transcription factors of key signaling pathways of limb development (WNT, SHH, FGF), and their deficiency causes a combination of abnormal finger and thumb development, abnormal facial development, and abnormal neurodevelopment. Disruption of the pattern of limb apoptosis in late embryonic development is proposed to cause abnormal finger formation.
In Holt-Oram syndrome, TBX5 simultaneously regulates determination of posterior upper limb tissue identity and cardiac development pathways. TBX5 interacts with GATA4 and is essential for atrial and ventricular septal development, and it also regulates genes involved in radius and hand formation (including interaction with TBX3). In TBX5-deficient mouse models, cardiac malformations and abnormal forelimb development are reproduced.
In nail-patella syndrome, LMX1B is a key transcription factor that determines the dorsal identity of the embryonic limb. With LMX1B deficiency, development of dorsal limb structures such as the nails, patella, iliac crest, and quadriceps tendon insertion fails. In the kidney, LMX1B regulates expression of COL4A3 and COL4A4, which make up the glomerular basement membrane, so LMX1B deficiency causes structural abnormalities of the glomerular basement membrane and proteinuria/nephrotic syndrome.
In Klippel-Trénaunay-Weber syndrome, PIK3CA activating variants overactivate the PI3K/AKT/mTOR signaling pathway, causing abnormal proliferation of vascular endothelial cells, abnormal development of veins and lymphatics, and overgrowth of fat and soft tissue. Because these are somatic mosaic variants, vascular malformations and hypertrophy appear confined to the limb in which the abnormal cells are present.
In VATER/VACTERL, a defect in the differentiation of embryonic mesoderm is understood to affect multiple organ systems in combination. Abnormalities in the WNT signaling pathway, sonic hedgehog (SHH) pathway, and BMP signaling pathway may affect vertebral segmentation, limb patterning, and ureteral and esophageal development, respectively. In maternal diabetes, the hyperglycemic environment is proposed to disrupt embryonic mesodermal differentiation signals, increasing the risk of VACTERL-associated anomalies.
The syndromes in this category each show a characteristic cluster of symptoms.
Broad, flat thumbs and great toes are the core hallmark. Radial deviation of the thumb, short fingers (brachydactyly), and polydactyly may be present. Intellectual disability is moderate (IQ 35–70), and spoken language development is particularly delayed. Distinctive facial features include arched eyebrows, long eyelashes, a beaked nose, downslanting palpebral fissures, cleft palate or high-arched palate, and a retruded chin. Short stature and microcephaly are present. As a behavioral phenotype, there is a tendency toward curiosity and high sociability, but attention-deficit/hyperactivity disorder (ADHD) and autism spectrum disorder may also be present. Cardiac malformations (ASD, VSD, PDA, etc.) accompany about 30%.
Upper limb malformation is an essential finding, ranging very widely from polydactyly or small fingers to severe radial defects (partial to complete radial aplasia), forearm shortening, and arm hypoplasia (phocomelia). The most common cardiac malformation is atrial septal defect (ostium secundum type most common), accompanied by ventricular septal defect, sinoatrial node dysfunction (bradycardia, atrioventricular block), and others. The severity of upper limb and cardiac malformations does not necessarily run in parallel, and mild upper limb malformations may coexist with severe cardiac malformations.
Characterized by a three-symptom complex of port-wine stain, abnormal venous and lymphatic malformations, and hypertrophy of one limb (mainly a lower limb). Limb hypertrophy affects both soft tissue and bone, enlarging one leg or arm and causing a length discrepancy. When arteriovenous fistulas are present (Weber variant), there is a risk of heart failure. Chronic pain, thrombophlebitis, deep vein thrombosis, and leg ulcers due to vascular malformations can occur.
Combines vertebral anomalies (hemivertebrae, segmentation anomalies), anal atresia, tracheoesophageal fistula and esophageal atresia, renal malformations (renal agenesis, horseshoe kidney, duplicated renal pelvis), cardiac malformations (VSD, ASD, TOF, etc.), and limb deficiencies (radial defects, polydactyly, syndactyly). It is rare for all components to appear in one patient, and three or more components are required for diagnosis. Tracheoesophageal fistula and esophageal atresia cause life-threatening emergencies in the neonatal period.
The four cardinal signs are nail dysplasia (triangular lunulae, absent or split nails), absent or hypoplastic patellae, iliac horns, and elbow dysplasia (inability to fully extend the elbow, subluxation). Nephrotic syndrome or glomerulonephritis occurs in about 30–50%, and proteinuria is the first sign of renal involvement. Elevated intraocular pressure and glaucoma accompany some cases.
The physical examination and ancillary test findings of each syndrome are as follows.
Characteristic physical findings of Rubinstein-Taybi syndrome: marked enlargement (flat and broad) and radial deviation of the thumbs and great toes, short and stubby fingers, polydactyly (about 7–10%), distinctive facial findings (arched eyebrows, downslanting palpebral fissures, beaked nose, thick septum, history of otitis media), hearing abnormalities, microcephaly (head circumference -2 SD or less). On radiography, broad distal phalanges of the thumb are characteristic. Echocardiography is needed to confirm structural malformations. Brain MRI shows abnormal corpus callosum development and ventricular dilation in some.
Physical findings of Holt-Oram syndrome: radial defect or shortening (confirmed on upper limb radiographs), finger abnormalities (trigger thumb, triphalangeal thumb, absent thumb), clavicular and sternal malformations. ECG may show right bundle branch block, prolonged PR interval, and atrioventricular block, and echocardiography confirms ASD (especially ostium secundum type) and VSD. The degree of radial defect (partial to complete) is evaluated on upper limb X-rays.
Findings in Klippel-Trénaunay-Weber syndrome: port-wine stains are observed on the skin of the affected limb, and venous dilation and varicose veins are prominent. Limb length discrepancy is confirmed by full-length radiographic measurement. Doppler ultrasound identifies venous, lymphatic, and arteriovenous malformation patterns, and MRA/MRV determine the extent of vascular malformations. Thrombocytopenia and hyperlipidemia may be present, and elevated D-dimer is used as an indicator of thrombotic activation.
Findings in VATER/VACTERL: anal atresia confirmed on inspection of the anus in the neonatal period; esophageal atresia suspected from resistance to nasogastric tube insertion. Abdominal X-ray shows air-fluid level patterns and vertebral anomalies (hemivertebrae, segmentation fusion). Cardiac malformations are evaluated by echocardiography, renal malformations confirmed by renal ultrasound, and radial defects and polydactyly identified by limb radiographs.
Findings in nail-patella syndrome: triangular lunulae of the nails and absent, split, or longitudinally ridged nails are characteristic. Patellar X-rays show hypoplasia, absence, or lateral displacement. On pelvic X-ray, iliac horns (pathognomonic) are a diagnostic finding. Early detection of proteinuria on urinalysis is important for screening for renal involvement.
Screening opportunities for the syndromes in this category exist at several stages: prenatal, neonatal, and childhood.
Prenatal screening: routine prenatal ultrasound (detailed ultrasound at 18–20 weeks of gestation) may detect limb abnormalities (simplification, deficiency, hypertrophy), cardiac malformations, vertebral and renal abnormalities, and more. When prenatal ultrasound shows a combination of nail and limb malformations, cardiac malformations, and renal malformations, the relevant syndrome is suspected and prenatal genetic testing is recommended. Prenatal MRI is used for additional evaluation when ultrasound is unclear.
Neonatal screening: on full-body physical examination immediately after birth, limb malformations (radial defects, syndactyly, polydactyly), thumb abnormalities, presence of the anal opening, and esophageal atresia (nasogastric tube insertion) are evaluated. Newborns suspected of VACTERL immediately undergo echocardiography, abdominal ultrasound, and spinal radiographs. In newborns with nail and patellar abnormalities, nail-patella syndrome is suspected and genetic testing is performed.
Childhood screening: Rubinstein-Taybi syndrome is often suspected in pediatrics or developmental pediatrics from developmental delay, thumb abnormalities, and distinctive facial findings. Holt-Oram syndrome can be screened, when there is a family history, by echocardiography and upper limb radiographic evaluation immediately after birth. In nail-patella syndrome, urine protein testing at least once a year is recommended to screen for renal involvement.
Family history–based screening: when there is a family with a confirmed syndrome, for autosomal dominant syndromes (Rubinstein-Taybi, Holt-Oram, nail-patella), the 50% recurrence risk for children is disclosed, and genetic testing immediately after birth or prenatally is recommended.
Diagnosis proceeds in the order of meeting clinical diagnostic criteria followed by molecular genetic confirmation.
The combination of broad thumbs and great toes, distinctive facial findings, and intellectual disability is clinically suggestive. Confirmed by direct sequencing of the CREBBP/EP300 genes (NGS panel or WES). Large deletions are detected by MLPA or CMA (chromosomal microarray). In about 35%, no pathogenic variant is identified even with current testing, so a negative result does not exclude the diagnosis.
The combination of upper limb malformation (at least one side) and cardiac malformation is the clinical diagnostic criterion. Confirmed by TBX5 gene sequencing, with deletions detected by MLPA. The family history must be investigated to determine whether the same syndrome is present in the family. Echocardiography, 24-hour Holter ECG monitoring, and radiographs of the entire upper limbs are standard evaluation items.
The presence of 2 or more of the 4 major criteria—nail dysplasia, absent or hypoplastic patellae, iliac horns, and elbow dysplasia—is strongly suggestive clinically. Confirmed by identification of an LMX1B gene variant. Renal function evaluation (urine protein, creatinine, glomerular filtration rate) is needed from the outset. Intraocular pressure measurement and glaucoma screening are also included.
The three-symptom complex of port-wine stain, vascular malformations, and limb hypertrophy is the clinical diagnostic criterion. Detection of somatic variants such as PIK3CA in skin biopsy or lesional tissue is used for molecular diagnosis. The extent and type of vascular malformations are determined by MRI/MRA/MRV, and D-dimer, platelets, and coagulation tests are performed to assess the risk of thrombotic complications.
Clinically diagnosed by the presence of 3 or more components (V, A, C, TE, E, R, L). Because there is no single confirmatory genetic test, excluding other genetic syndromes (CHARGE, Down, trisomy 18, etc.) by chromosomal microarray and WES is the priority. Multi-organ evaluation (echocardiography, abdominal and renal ultrasound, spinal radiographs, upper gastrointestinal contrast study, anal evaluation) is essential.
There is still no curative treatment for the syndromes in this category, and multidisciplinary symptomatic treatment of each malformation and complication is central.
Early educational intervention for intellectual disability and developmental delay (special education, speech therapy, occupational therapy, physical therapy) is key. When thumb malformations impair function, surgical correction (e.g., correction of radial deviation) is performed. Associated cardiac malformations are treated by surgery or catheter intervention depending on the type. Behavioral and pharmacological treatment for ADHD, autism spectrum disorder, and anxiety may be needed. Regular hearing tests, ophthalmological examinations (refractive errors, strabismus), and scoliosis monitoring are included.
Cardiac malformations (ASD, VSD) are corrected by percutaneous closure or open-heart surgery. When atrioventricular block progresses, pacemaker implantation is required. Upper limb malformations are approached with functional rehabilitation (occupational therapy), customized assistive devices, and orthopedic surgery as needed (radial correction, finger reconstruction). Because cardiac complications are the main prognostic determinant, regular follow-up by a cardiologist is essential.
Compression stockings relieve venous congestion and lymphedema. For vascular malformations, sclerotherapy (absolute ethanol, foam sclerosants), laser treatment (port-wine stains), surgical excision, and other treatments are applied in stages. When arteriovenous fistulas burden the heart, embolization or surgical treatment is needed. When the limb length discrepancy is large, orthopedic correction (epiphysiodesis, limb lengthening) is performed. Clinical trial results are being reported showing that mTOR inhibitors (everolimus, sirolimus) are effective for PIK3CA-related vascular malformations.
In the neonatal period, emergency surgery for tracheoesophageal fistula and esophageal atresia, anoplasty, and other procedures are performed. Cardiac and renal malformations receive standard treatment according to the type and severity of each malformation. For limb malformations, functional reconstructive surgery and assistive devices (including prostheses) are used. Multidisciplinary coordination is essential, and collaboration among pediatric gastrointestinal surgery, cardiac surgery, urology, orthopedics, and neonatal intensive care specialists is important.
For renal involvement, angiotensin-converting enzyme inhibitors (ACE inhibitors) or angiotensin receptor blockers (ARB) are used early to reduce proteinuria. When it progresses to renal failure, dialysis or kidney transplantation is required. Medical and surgical treatment of glaucoma and physical therapy and surgical correction for elbow dysplasia are included.
The prognosis of the syndromes in this category differs greatly depending on the type and severity of associated malformations.
In Rubinstein-Taybi syndrome, the main life-threatening risk factors are cardiac malformations and recurrent infections (immune dysfunction). Intellectual disability is moderate, but considerable functional improvement is possible through early intervention and special education. Many patients survive into adulthood, and some can live independently or semi-independently through social skills and vocational training. There are reports that the risk of malignant tumors (leukemia, medulloblastoma, etc.) is higher than in the general population, so tumor monitoring is recommended.
With appropriate cardiac treatment, a normal or near-normal life expectancy can be expected in Holt-Oram syndrome. When atrioventricular block progresses and a pacemaker is implanted, ongoing cardiac follow-up is needed. Upper limb malformations affect function, but daily life and occupational activities are possible with rehabilitation and assistive devices.
The prognosis of Klippel-Trénaunay-Weber syndrome is determined by the extent of vascular malformations and the presence of arteriovenous fistulas. Deep vein thrombosis, pulmonary embolism, and bleeding complications are the main causes of death. Chronic pain, reduced limb function, and psychological difficulties affect quality of life. Complications can be reduced by active management of vascular malformations and thrombosis prevention.
The prognosis of VATER/VACTERL varies with the extent and severity of the component malformations. Cardiac and renal malformations are the main long-term prognostic determinants. Survival after repair of esophageal atresia and tracheoesophageal fistula has improved markedly with advances in modern neonatal intensive care. When the extent of malformations is limited, a normal life into adulthood is possible.
In nail-patella syndrome, the presence of renal involvement is the most important prognostic factor. Progression to renal failure is reported in about 5–10%. The prognosis after kidney transplantation is good. With appropriate treatment of glaucoma, vision can be preserved.
Because most syndromes in this category are hereditary, the core of prevention is genetic counseling and prenatal and preimplantation genetic testing.
Genetic counseling: for autosomal dominant syndromes (Rubinstein-Taybi, Holt-Oram, nail-patella), patients are counseled that each child has a 50% recurrence risk. When the condition arose from a de novo mutation, the possibility of parental germline mosaicism (about 1–2%) must be considered, so parents are informed that even with a de novo variant in the first child, the recurrence risk in the next pregnancy is not completely zero. Genetic testing is also recommended for the extended family (siblings, parents) of families with an identified gene variant.
Prenatal diagnosis: when the causative gene is known, fetal genetic analysis by chorionic villus sampling (CVS) at 10–12 weeks of gestation or amniocentesis at 15–18 weeks of gestation is possible. Early detection of limb, cardiac, and renal abnormalities on routine prenatal ultrasound helps with prenatal counseling and postnatal preparation.
Preimplantation genetic testing (PGT-M): when in vitro fertilization (IVF) is chosen, prevention without termination of pregnancy is possible by genetic testing of embryos before transfer and selectively transferring embryos that do not carry the pathogenic variant.
Because Klippel-Trénaunay-Weber syndrome and VATER/VACTERL mostly occur sporadically, family history–based prevention is limited, but optimal control of maternal diabetes (related to VATER) and avoidance of exposure to teratogens (valproic acid, estrogen) during pregnancy may help reduce risk.
Expanding newborn screening and building infrastructure for early diagnosis are important for secondary prevention (prevention of complications through early treatment). In particular, in Holt-Oram syndrome, regular ECG and echocardiographic follow-up for early detection of atrioventricular block contributes to the prevention of sudden death.